Skip to main content

Completed · Netherlands · Pharma and biotech

Ambrose Healthcare acquires AM-Pharma.

UK rare-disease company Ambrose Healthcare (Cambridge) acquired 100% of Utrecht-based AM-Pharma, developer of the enzyme therapy ilofotase alfa for hypophosphatasia, announced on 20 October 2026. The deal gives Ambrose its first European base. The deal completed on 20 October 2026.

SigningDay 100

Announced 20 October 2026 · Day 100 on 28 January 2027

Buyer
Ambrose Healthcare ·Cambridge, United Kingdom
Target
AM-Pharma B.V. ·Utrecht, Netherlands
Type
Acquisition
Announced
20 October 2026
Completed
20 October 2026
Value
up to EUR 161 million
People
Not stated in the release
Last checked
28 October 2026

The people side in the Netherlands

Related deals

Get the briefing

Deals into Europe lists public facts with their sources, checked every working day by Octagon Professionals International. Corrections go to info@octagon.nl and are made within one working day. How we track deals.

Enabling organisations to operate across borders with clarity, compliance, and trust.

All deals into Europe